Diabetes Metab J > Volume 46(5); 2022 > Article |
|
CONFLICTS OF INTEREST
In-Kyung Jeong was editor in chief of the Diabetes & Metabolism Journal from 2020 to 2021. Kyu Yeon Hur and Sung Hee Choi were editorial board member of the Diabetes & Metabolism Journal from 2020 to 2021. Jung Hyun Noh was associate editor of the Diabetes & Metabolism Journal from 2020 to 2021. They were not involved in the review process of this article. Otherwise, there was no conflict of interest.
AUTHOR CONTRIBUTIONS
Conception or design: H.J.K., S.H.C.
Acquisition, analysis, or interpretation of data: H.J.K, I.K.J., K.Y.H., S.K.K., J.H.N., S.W.C., E.S.K., E.J.R., S.H.C.
Drafting the work or revising: H.J.K., I.K.J., S.H.C.
Final approval of the manuscript: H.J.K, I.K.J., K.Y.H., S.K.K., J.H.N., S.W.C., E.S.K., E.J.R., S.H.C.
FUNDING
The study was funded by the Takeda Pharmaceutical Company limited, Japan and Takeda Pharmaceutical Company limited, Korea with the initiation of investigator proposal of the study. 'Takeda' had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Values are presented as mean±standard deviation or number (%). P values were applied by analysis of variance (ANOVA) with Bonferroni for continuous variables and Pearson chi-square test for categorical variables.
GLIM, glimepiride; ALO, alogliptin; ALO-PIO, alogliptin-pioglitazone; BMI, body mass index; DM, diabetes mellitus; HbA1c, glycosylated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GT, glutamyl transpeptidase; BUN, blood urea nitrogen; PAOD, peripheral arterial occlusive disease; RAS, renin-angiotensin system.
Values are presented as mean±standard deviation in baseline, and change at week 12 and week 24 data are adjusted mean±standard error. P values were applied by analysis of covariance (ANCOVA; adjusted variable: baseline value) with Bonferroni for continuous variables and Pearson chi-square test adjusted by Bonferroni for categorical variables.
GLIM, glimepiride; ALO, alogliptin; ALO-PIO, alogliptin-pioglitazone; HbA1c, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
Values are presented as mean±standard deviation in baseline, and change at week 24 data are adjusted mean±standard error. P values were applied by analysis of variance (ANOVA) with Bonferroni for baseline values and analysis of covariance (ANCOVA; adjusted variable: baseline value) with Bonferroni for adjusted mean change at week 24.
GLIM, glimepiride; ALO, alogliptin; ALO-PIO, alogliptin-pioglitazone; SD, standard deviation; CONGA, continuous overall net glycemic action; HBGI, High Blood Glucose Index; MODD, mean of daily differences; MAGE, mean amplitude of glucose excursions; ADDR, average daily risk range.
Hae Jin Kim
https://orcid.org/0000-0002-8958-7164
Sung Hee Choi
https://orcid.org/0000-0003-0740-8116
Takeda Pharmaceutical Company
https://doi.org/10.13039/100008373
Takeda Pharmaceutical Company limited, Korea